Pharmapark Will Market Prestige's Trastuzumab In Russia

Prestige BioPharma has struck a deal with Pharmapark to market Prestige’s trastuzumab biosimilar in the Russian Federation.

Russia
The Russian Deal Comes Hot On the Heels Of A European Tie-Up With Mundipharma • Source: Shutterstock

Prestige BioPharma has announced that Pharmapark will market its trastuzumab biosimilar in the Russian Federation under the terms of a deal that has just been agreed between the two companies.

The biosimilar rival to Roche’s Herceptin was recently accepted for review by the European Medicines Agency, with Prestige citing “excellent...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business